The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) by Coissac Patrice since 2010.
The trader's CIK number is 1341212.
At the time of the last reporting, Coissac Patrice was the GM/President ALXN SAS Europe of Alexion Pharmaceuticals, Inc.. (stock ticker symbol ALXN).
Also see all insider trading activities at Alexion Pharmaceuticals, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2012 | ALXN | 0 | $0 | 238,247 | $22,179,379 | 161,483 | $3,882,394 |
| 2011 | ALXN | 0 | $0 | 169,866 | $14,088,455 | 169,866 | $2,734,443 |
| 2010 | ALXN | 0 | $0 | 3,900 | $262,002 | 3,900 | $54,912 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2012-10-31 | ALXN | Sale | 84,764 | 91.38 | 7,745,480 |
| 2012-08-27 | ALXN | Option Ex | 41,932 | 32.78 | 1,374,530 |
| 2012-08-28 | ALXN | Option Ex | 21,551 | 42.66 | 919,365 |
| 2012-08-27 | ALXN | Sale | 41,932 | 107.05 | 4,488,820 |
| 2012-08-28 | ALXN | Sale | 21,551 | 106.37 | 2,292,379 |
| 2012-02-23 | ALXN | Option Ex | 90,000 | 17.65 | 1,588,499 |
| 2012-02-23 | ALXN | Sale | 90,000 | 85.03 | 7,652,700 |
| 2012-02-03 | ALXN | Option Ex | 8,000 | .00 | 0 |
| 2011-11-16 | ALXN | Option Ex | 72,766 | 17.41 | 1,266,856 |
| 2011-11-16 | ALXN | Sale | 72,766 | 66.87 | 4,865,862 |
| 2011-03-10 | ALXN | Option Ex | 45,000 | 18.46 | 830,925 |
| 2011-03-10 | ALXN | Sale | 45,000 | 97.47 | 4,386,150 |
| 2011-02-17 | ALXN | Option Ex | 52,100 | 12.22 | 636,662 |
| 2011-02-17 | ALXN | Sale | 52,100 | 92.83 | 4,836,443 |
| 2010-10-27 | ALXN | Option Ex | 3,900 | 14.08 | 54,912 |
| 2010-10-27 | ALXN | Sale | 3,900 | 67.18 | 262,002 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Coissac Patrice (GM/President ALXN SAS Europe of Alexion Pharmaceuticals, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.